Spots Global Cancer Trial Database for tamoxifen
Every month we try and update this database with for tamoxifen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| Decision Aids for Tamoxifen Treatment in Breast Cancer Patients | NCT02488603 | Breast Cancer | Decision aids (... tamoxifen | 18 Years - | National Cancer Center, Korea | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 | NCT00900744 | Breast Cancer | Tamoxifen | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | NCT01685255 | Ovarian Cancer Genitourinary (... | Epacadostat tamoxifen | 18 Years - | Incyte Corporation | |
| Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device | NCT04116827 | Sleep Disorder Breast Cancer | Tamoxifen Oral ... | 18 Years - 45 Years | Samsung Medical Center | |
| The Ultrasound Study of Tamoxifen | NCT01582074 | Breast Neoplasm... | 30 Years - 70 Years | National Institutes of Health Clinical Center (CC) | ||
| Liver Safety Under Upfront Arimidex vs Tamoxifen | NCT00537771 | Breast Cancer | Anastrozole Tamoxifen | - | AstraZeneca | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment | NCT00605267 | Breast Cancer | Tamoxifen Anastrazole (Ar... Goserelin aceta... | 20 Years - | AstraZeneca | |
| Maintenance Hormonal Therapy and DLBCL | NCT06355401 | Diffuse Large B... | Tamoxifen 20mg | 18 Years - 75 Years | Sohag University | |
| Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer | NCT00293540 | Breast Cancer | oophorectomy Tamoxifen | 18 Years - | International Breast Cancer Research Foundation | |
| Tamoxifen Versus Etoposide After First Recurrence in GBM Patients | NCT04765098 | Glioblastoma Mu... | Tamoxifen Etoposide | 18 Years - 65 Years | AHS Cancer Control Alberta | |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | NCT06195306 | Breast Atypical... Breast Carcinom... Breast Ductal C... Breast Lobular ... | Biospecimen Col... Mammography Omega-3-Acid Et... Questionnaire A... Random Periareo... Tamoxifen | 45 Years - 65 Years | National Cancer Institute (NCI) | |
| Reversing Therapy Resistance With Epigenetic-Immune Modification | NCT02395627 | Breast Neoplasm... | Tamoxifen Vorinostat Pembrolizumab | 18 Years - | University of California, San Francisco | |
| SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer | NCT00005822 | Breast Cancer | doxorubicin hyd... semaxanib conventional su... radiation thera... tamoxifen | 18 Years - | Case Comprehensive Cancer Center | |
| Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients | NCT03931928 | Breast Cancer DCIS | (Z)-Endoxifen s... (Z)-Endoxifen s... | 18 Years - | Robert Bosch Gesellschaft für Medizinische Forschung mbH | |
| Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up | NCT01357772 | Carcinoma, Intr... Recurrence, Loc... Breast Neoplasm... Atypical Hyperp... | Tamoxifen placebo | 18 Years - 75 Years | Ente Ospedaliero Ospedali Galliera | |
| German Preoperative Adriamycin Docetaxel Study | NCT00543829 | Breast Neoplasm... | doxorubicin, do... doxorubicin, do... | 18 Years - 70 Years | German Breast Group | |
| Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane | NCT02728622 | Ovarian Cancer Peritoneal Canc... Cancer of the F... | Tamoxifen Chemotherapy | 18 Years - | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Hemostatic Profiles of Endocrine Therapies for Breast Cancer | NCT03381963 | Breast Neoplasm... Venous Thromboe... | 18 Years - | University Hospital, Geneva | ||
| Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients | NCT00309491 | Early-stage Bre... | Tamoxifen alone Tamoxifen + Ami... | 50 Years - 80 Years | Austrian Breast & Colorectal Cancer Study Group | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | NCT03280563 | Breast Neoplasm... | Atezolizumab (M... Bevacizumab Entinostat Exemestane Fulvestrant Ipatasertib Tamoxifen Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression | NCT02584465 | Ovarian Carcino... | Tamoxifen Regorafenib | 18 Years - | ARCAGY/ GINECO GROUP | |
| Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer | NCT04272801 | Breast Cancer F... | tamoxifen, letr... Patient reporte... | 65 Years - | University of Virginia | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| Reversing Therapy Resistance With Epigenetic-Immune Modification | NCT02395627 | Breast Neoplasm... | Tamoxifen Vorinostat Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen | NCT03582865 | Breast Cancer | Tamoxifen 20 mg | 20 Years - 50 Years | Assiut University | |
| PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY | NCT03423199 | Breast Neoplasm... | Palbociclib Placebo Tamoxifen Goserelin | 18 Years - | National Cancer Center, Japan | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women | NCT00912548 | Breast Cancer | goserelin tamoxifen | 18 Years - 45 Years | Korean Breast Cancer Study Group | |
| Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer | NCT02404844 | Breast Cancer | BKM120 Tamoxifen | 18 Years - | University Hospital, Essen | |
| Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors | NCT01758146 | Breast Cancer | Tamoxifen Letrozole | 45 Years - 80 Years | PGIMER | |
| Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | NCT00206492 | Breast Cancer | Iressa Tamoxifen | 18 Years - | Baylor Breast Care Center | |
| Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer | NCT00884143 | Post Menopausal Breast Cancer | - | AstraZeneca | ||
| Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women | NCT02914158 | Breast Cancer | Goserelin Tamoxifen Aromatase Inhib... Leuprolide | - 35 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Casodex - Nolvadex Combination | NCT00637871 | Gynaecomastia Prostate Cancer | Casodex Tamoxifen | - | AstraZeneca | |
| Tamoxifen Pharmacogenetics in Asian Breast Cancer Women | NCT01181518 | Poisoning by, A... | 18 Years - | Inje University | ||
| Tamoxifen Pharmacogenetics and Clinical Effects | NCT00228930 | Breast Cancer | Tamoxifen (phar... | 18 Years - 70 Years | National Institute of General Medical Sciences (NIGMS) | |
| Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | NCT05101564 | Breast Cancer HER2-negative B... ER Positive Bre... | Alpelisib Tamoxifen Zotatifin Fulvestrant | 18 Years - | Stanford University | |
| Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer | NCT00365599 | Breast Cancer | suberoylanilide... tamoxifen citra... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | NCT00171704 | Hormone Sensiti... | Letrozole Tamoxifen | 50 Years - | Novartis | |
| Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | NCT04190056 | Anatomic Stage ... Prognostic Stag... | Pembrolizumab Tamoxifen Vorinostat | 18 Years - | University of California, San Francisco | |
| Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI | NCT01297231 | Breast Cancer | MRI | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ | NCT04666961 | Ductal Carcinom... Extensive Disea... Mastectomy | Tamoxifen 20 mg Anastrozole 1Mg... | 40 Years - | Institut Cancerologie de l'Ouest | |
| A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix | NCT02482740 | Uterine Cervica... | Letrozole tamoxifen | 30 Years - 85 Years | Buddhist Tzu Chi General Hospital | |
| Stellate Ganglion Block (SGB) For Women for Breast Cancer | NCT02513329 | Hot Flushes Hot Flashes | Bupivicaine Saline | 30 Years - 70 Years | Northwestern University | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | NCT00919399 | Breast Neoplasm... | Exemestane tamoxifen | 60 Years - | Institut Claudius Regaud | |
| Tamoxifen Prediction Study in Patients With ER+ Breast Cancer | NCT05525481 | ER+ Breast Canc... | Tamoxifen | 18 Years - | Erasmus Medical Center | |
| Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | NCT02936206 | Breast Cancer | Fulvestrant Tamoxifen | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study | NCT05801705 | Hormone-recepto... Premenopausal B... Breast Cancer P... Ovarian Functio... | Aromatase inhib... ovarian functio... Tamoxifen toremifene | 18 Years - 60 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer | NCT00210028 | Breast Neoplasm... | Tamoxifen Zarnestra | 18 Years - | Institut Claudius Regaud | |
| Hemostatic Profiles of Endocrine Therapies for Breast Cancer | NCT03381963 | Breast Neoplasm... Venous Thromboe... | 18 Years - | University Hospital, Geneva | ||
| Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | NCT00038467 | Breast Neoplasm... | Tamoxifen Exemestane | 30 Years - | Pfizer | |
| Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer | NCT00053339 | Stage IV Breast... Recurrent Breas... | tamoxifen trastuzumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen | NCT03504631 | Breast Cancer F... | No intervention | - | Trisakti University | |
| Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer | NCT00053339 | Stage IV Breast... Recurrent Breas... | tamoxifen trastuzumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women | NCT00003906 | Breast Cancer | Raloxifene Tamoxifen | 35 Years - | NSABP Foundation Inc | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women | NCT00808522 | Breast Cancer | hCG | 30 Years - 75 Years | New York Presbyterian Hospital | |
| Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | NCT00038467 | Breast Neoplasm... | Tamoxifen Exemestane | 30 Years - | Pfizer | |
| A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors | NCT03707340 | Breast Cancer Hyposexual Desi... | Flibanserin Pil... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix | NCT02482740 | Uterine Cervica... | Letrozole tamoxifen | 30 Years - 85 Years | Buddhist Tzu Chi General Hospital | |
| Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients | NCT01638247 | Male Breast Can... | Tamoxifen Tamoxifen and G... Exemestane and ... | 18 Years - 85 Years | German Breast Group | |
| Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | NCT00206492 | Breast Cancer | Iressa Tamoxifen | 18 Years - | Baylor Breast Care Center | |
| A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen | NCT01223833 | Breast Cancer Arthralgia | 18 Years - | Universitaire Ziekenhuizen KU Leuven | ||
| Breast Cancer & Antiestrogenic Therapy & Brain | NCT06346457 | Breast Cancer F... Healthy Female Menopause Anti-estrogenic... | Tamoxifen Letrozole Letrozole + GnR... | 18 Years - 70 Years | International Research Training Group 2804 | |
| Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+ | NCT01220076 | Non Metastatic ... | tamoxifen | 18 Years - | Institut Cancerologie de l'Ouest | |
| A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | NCT04200066 | Glioblastoma Brain Tumor | Temozolomide, T... | 18 Years - | University of Rochester | |
| Tamoxifen for the Prevention of Breast Cancer in High-Risk Women | NCT00002644 | Breast Cancer | Tamoxifen Citra... Placebo | 35 Years - 70 Years | Queen Mary University of London | |
| Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer | NCT00293540 | Breast Cancer | oophorectomy Tamoxifen | 18 Years - | International Breast Cancer Research Foundation | |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | NCT02057133 | Breast Neoplasm... | LY2835219 Letrozole Anastrozole Tamoxifen Exemestane Everolimus Trastuzumab LY3023414 Fulvestrant Pertuzumab Loperamide Endocrine thera... | 18 Years - | Eli Lilly and Company | |
| ATAC - Bone Density Sub-Protocol | NCT00784940 | Bone Density | Anastrozole Tamoxifen | 45 Years - | AstraZeneca | |
| Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer | NCT00053339 | Stage IV Breast... Recurrent Breas... | tamoxifen trastuzumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma | NCT00847366 | Non Small Cell ... Solid Tumors Metastatic Brea... Sarcomas | Perifosine Trastuzumab Tamoxifen | 18 Years - | AEterna Zentaris | |
| ETHAN - ET for Male BC | NCT05501704 | Male Breast Can... Hormone Recepto... Hormone Recepto... | Tamoxifen Anastrozole Degarelix Abemaciclib | 18 Years - | Dana-Farber Cancer Institute | |
| Adjuvant Post-Tamoxifen Exemestane Trial | NCT00810706 | Breast Cancer | exemestane | 18 Years - 80 Years | Hellenic Breast Surgeons Society | |
| German Preoperative Adriamycin Docetaxel Study | NCT00543829 | Breast Neoplasm... | doxorubicin, do... doxorubicin, do... | 18 Years - 70 Years | German Breast Group | |
| Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | NCT06179303 | Anatomic Stage ... Anatomic Stage ... Locally Advance... Locally Advance... Metastatic HER2... Metastatic Horm... | Abemaciclib Anastrozole Biospecimen Col... Computed Tomogr... Diagnostic Imag... Exemestane Fludeoxyglucose... Fluorine F 18 F... Fulvestrant Gonadotropin-re... Letrozole Positron Emissi... Tamoxifen Therapeutic Est... | 18 Years - | University of Washington |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
